A Double-Blind, Randomized, Parallel, Two-Arm Phase H Trial of BMS-690514 versus Erlotinib in Previous Chemotherapy-Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Safety Review

被引：0
|
作者：
Sbar, E. [1 ]
Besse, B. [2 ]
Felip, E. [3 ]
Shaw, A. [4 ]
Ahn, M. [5 ]
Salvati, M. [1 ]
Bhagavatheeswaran, P. [1 ]
Soria, J. [2 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Hosp Valle De Hebron, Barcelona, Spain
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S538 / S539
页数：2
相关论文
共 50 条
  • [21] Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer
    Spigel, David R.
    Burris, Howard A., III
    Greco, F. Anthony
    Shipley, Dianna L.
    Friedman, Elke K.
    Waterhouse, David M.
    Whorf, Robert C.
    Mitchell, R. Brian
    Daniel, Davey B.
    Zangmeister, Jeffrey
    Bass, J. David
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2582 - 2589
  • [22] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).
    Tran, HT
    Zinner, R
    Blumenschein, GR
    Oh, YW
    Papadimitrakopoulou, VA
    Kim, ES
    Lu, C
    Malik, M
    Lum, B
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [23] PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).
    Sorlini, C.
    Barni, S.
    Petrelli, F.
    Novello, S.
    De Marinis, F.
    De Pas, T. M.
    Grossi, F.
    Bearz, A.
    Mencoboni, M.
    Aieta, M.
    Caprioli, A.
    Antonelli, P.
    Zilembo, N.
    Bachi, A.
    Floriani, I.
    Roder, H.
    Roder, J.
    Grigorieva, J.
    Lazzari, C.
    Gregorc, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    RESPIROLOGY, 2014, 19 : 165 - 165
  • [25] Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried E. E.
    O'Brien, Mary E. R.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Hoffman, Philip C.
    Orlov, Sergey V.
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4007 - +
  • [26] ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)-A randomized double-blind phase III study.
    Boyer, Michael J.
    Janne, Pasi A.
    Mok, Tony
    O'Byrne, Kenneth John
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Liang, Jane Q.
    Taylor, Ian
    Campbell, Alicyn
    O'Connell, Joseph P.
    Letrent, Stephen P.
    Antic, Vladan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [29] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    De Boer, R.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    Vansteenkiste, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for firstline chemotherapy
    Lee, S.
    Rudd, R.
    Khan, I.
    Upadhyay, S.
    Lewanski, C. R.
    Falk, S.
    Skailes, G.
    Partridge, R.
    Ngai, Y.
    Boshoff, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345